A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; GO 203 2c (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 09 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2019.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology